PCM
EIDX

Penserra Capital Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Penserra Capital Management’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-890
Closed -$117K – 1159
2020
Q4 		$117K Buy
890
+560
+170% +$49.5K ﹤0.01% 591
2020
Q3 		$16K Buy
+330
New +$14.8K ﹤0.01% 768

Penserra Capital Management's EIDX Position: Q1 2021 in Review

Penserra Capital Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 890 shares — an estimated $117K sold.

Penserra Capital Management first reported a position in EIDX in Q3 2020 and held it in 2 quarters. The position peaked at $117K in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

  • Penserra Capital Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Penserra Capital Management sold 890 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $117K.
  • Penserra Capital Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Penserra Capital Management's Eidos Therapeutics, Inc. Common Stock position peaked at $117K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Penserra Capital Management's 13F filing for Q1 2021, filed 13 May 2021.